Danske Bank A/S
10 February 2021
Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.
Akelius Residential Property Financing B.V.
Post-stabilisation Period Announcement
Further to the pre-stabilisation period announcement dated 9 February 2021, Danske Bank A/S (contact: Syndicate – Morten Grove; telephone: + 45 45 14 70 33) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
Securities
Issuer: | Akelius Residential Property Financing B.V. |
Guarantor(s) (if any): | Akelius Residential Property AB (publ) |
Aggregate nominal amount: | EUR 600,000,000 |
Description: | EUR 600,000,000 0.750 per cent. Unsecured Fixed Rate Notes due 22 February 2030, ISIN: XS2301127119 |
Offer price: | 98.983 per cet. |
Stabilisation Manager(s)
Name(s): | BNP Paribas, Danske Bank and Swedbank |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Robex Resources Inc.18.9.2025 08:01:56 CEST | Press release
Robex Announces Acceleration of Warrant Expiry Date
ONWARD Medical NV18.9.2025 07:30:00 CEST | Press release
Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy
Sampo plc18.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 17 September 2025
Biotalys NV18.9.2025 07:00:00 CEST | Press release
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
F. Hoffmann-La Roche Ltd18.9.2025 07:00:00 CEST | Press release
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom